Trial Profile
A Retrospective, Observational study to evaluate the real-world outcomes of liposomal irinotecan (nal-IRI) in patients with metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ipsen Biopharmaceuticals
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium
- 14 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology